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In a previous issue of *Arthritis Research and Therapy*, Ursum and colleagues report data showing that the anticitrullinated protein/peptide antibody (ACPA) status is significantly more stable than that of IgM rheumatoid factors (RFs) during the course of rheumatoid arthritis (RA) \[[@B1]\] - a finding that is fully consistent with previous reports \[[@B2]\]. They also found that the frequency of ACPA positivity is unrelated to age in RA patients and in the few ACPA-positive patients with non-RA disease, whereas RF positivity displayed age-related increases in patients with non-RA disease and it was also more closely correlated with acute-phase inflammatory markers. These findings, which are based on serological studies in over 18,000 patients attending outpatient rheumatology clinics, add to a steadily growing body of evidence highlighting the distinct natures of these two autoantibody systems.

Differential accuracy in the diagnosis of RA
============================================

ACPAs are considered the most accurate serological marker for RA \[[@B3]\]. ACPA seropositivity is rarely detected in non-RA patients, although it is occasionally associated with psoriatic arthritis, tuberculosis, leprosy, and autoimmune hepatitis, and its specificity for RA (over 96% when measured with second-generation ELISA) \[[@B4]\] is clearly superior to that of RF. In contrast, IgG RF, IgA RF, or IgM RF are a frequent finding in patients with other autoimmune disorders, in those with infectious diseases (where its prevalence depends on the primary/secondary nature of the infection, as well as on its duration), and even in healthy individuals, especially those who are elderly. The sensitivity of ACPAs is less impressive (around 68%) \[[@B4]\], but better results (82%) have been reported with assays measuring anti-Sa, the subset of ACPAs directed against modified citrullinated vimentine \[[@B5]\]. Anti-Sa positivity also appears to be a better predictor of radiographic progression in patients with early RA.

Anticitrullinated protein/peptide antibody role in synovial injury
==================================================================

Citrullinated proteins originate in the synovium, and ACPAs are produced in the inflamed synovium by local plasma cells. ACPAs \[[@B6]\] and ACPA-producing B cells have both been detected in synovial fluid from RA patients. The central role of these autoantibodies in the pathogenesis of RA has been demonstrated in a mouse model \[[@B7]\]. More recently, ectopic lymphoid structures in the synovia of some RA patients have been shown to support ongoing production of class-switched ACPAs \[[@B8]\].

Correlation between anticitrullinated protein/peptide antibodies and genetic determinants of RA
===============================================================================================

The HLA-DRB1 shared epitope alleles are a major genetic risk factor for RA. Their presence is associated with ACPA-positive forms of RA, and they also influence the magnitude of the ACPA response \[[@B9]\]. IgM RF has not been linked to any of the genetic risk factors for RA.

Temporal characteristics of anticitrullinated protein/peptide antibodies and RF expression in RA
================================================================================================

ACPAs and RFs are both potential components of the specific autoantibody response that characterizes the preclinical phase of RA \[[@B10]\], but ACPA positivity is likely to develop earlier and its presence may contribute to the subsequent appearance of RFs \[[@B11]\]. Later, with the onset of clinical RA, ACPA titers rise as a reflection of immune response maturation and increasing epitope dominance \[[@B12]\].

Conclusion
==========

Together with the new data of the Ursum group, the findings discussed above strongly support the view that ACPAs are a disease-specific marker of RA detectable early in the preclinical phase of the disease. In contrast, IgM-RF sero-positivity is generally a somewhat later event, and it is primarily a reflection of an inflammatory process that amplifies the tissue injury already underway. As Nowak and Newkirk have noted, the RF response may well be part of a normal host defense that - in this particular setting - is transformed into a threat to tissue integrity \[[@B13]\]. An interesting focus for future studies would be the characterization of ACPA (particularly anti-Sa) patterns in RA patients with partial responses to treatment consisting of the remission of signs and symptoms of inflammation coupled with ongoing radiographic progression.
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